Cannabidiol and Escitalopram: Faster Behavioral Effects in Stress Models
CBD SSRI adjunctive therapy shows promise in reducing the latency of antidepressant effects. This preclinical study highlights faster behavioral improvements with combined treatment. The findings suggest potential clinical relevance for mood disorder…
Exploring Neuroprotective Effects of Phytocannabinoids in Stroke Models
Phytocannabinoids neuroprotection stroke research explores their potential to reduce neuronal damage in stroke. This study used oxygen-glucose deprived neurons to model stroke conditions. Findings highlight modest neuroprotective effects of certain…
Cannabis Clinical Updates March 24 2026: Latest Articles
This post presents cannabis clinical updates March 24 2026, featuring 11 articles reviewed below the clinical relevance threshold. Topics include aging-related immune dysfunction, regulatory enforcement, and product innovation. These updates provide…
Endocannabinoid System Research: Cannabis for PTSD & SUDs
Endocannabinoid system research cannabis PTSD meta-analysis reveals trauma-focused treatments remain effective for individuals using cannabis. People with PTSD and co-occurring substance use disorders show comparable outcomes regardless of cannabis use.…
The Endocannabinoid System in Obsessive-Compulsive Disorder: A Scoping Review.
About 40% of individuals with obsessive-compulsive disorder do not respond to current treatments. This review focuses on endocannabinoid system OCD research, emphasizing preclinical evidence. Understanding ECS modulation may inform future therapeutic…
Stop chasing THC percentages — the strongest weed isn’t always the best high. Mid-range THC + the right terpenes can hit
Cannabinoid potency is only half the story, the terpenoid profile and individual receptor sensitivity determine actual clinical outcomes. A well-balanced cultivar at 15-18% THC with optimal myrcene and limonene ratios often outperforms a 30% THC dominant…
Enhancing Endocannabinoid System for Residual Disease in MS
This clinical study endocannabinoid system approach addresses residual disease in relapse-free multiple sclerosis patients. High-efficacy therapies reduce relapses but symptoms persist. Enhancing the endocannabinoid system offers new treatment insights.
Targeting the LPI/GPR55 Axis in MAFLD and MASH: Novel Insights, Therapeutic Strategies and Future Directions.
The LPI GPR55 receptor axis plays a crucial role in metabolic dysfunction-associated fatty liver disease (MAFLD). This pathway contributes to liver fat accumulation, inflammation, and fibrosis. Understanding this axis offers novel insights into potential…
Personalized Resilience: Variability in Brain-Immune Stress Responses
Brain-immune responses to stress vary significantly among individuals, influencing anxiety disorder development. This variability affects HPA axis regulation and immune function. Understanding these responses is key to personalized resilience strategies.
Cannabis for Pain Management: A Smarter Way to Think About Relief
Cannabis for pain relief requires matching the product, dose, and timing to the specific type of pain you have. Effective pain management with cannabis involves understanding cannabinoid roles and delivery methods. This guide helps you think clearly…
